Cancer Genetics (CGIX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CGIX Hot Sheet
Join SI Premium – FREE
Cancer Genetics (NASDAQ: CGIX) reported Q4 EPS of ($0.49), $0.01 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $4 million versus the consensus estimate of $3.7 million.
For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- LTC Properties (LTC) Tops Q3 EPS by 22c
- JELD-WEN Holding, Inc. (JELD) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
